

GENEXTRA FURTHER INVESTS \$25 MILLION SERIES B FINANCING IN INTERCEPT PHARMACEUTICALS

Dr. Lorenzo Tallarigo Appointed Chairman

MILAN, January 25, 2010 -- Genextra S.p.A., a privately held holding of companies active in the life science sector, today announced the completion of a \$25 million Preferred Series B financing in Intercept Pharmaceuticals, a clinical stage company developing novel therapeutics for chronic fibrotic and metabolic diseases. Genextra, already the major shareholder in Intercept, was the sole participant to the round.

In conjunction with the financing, Dr. Lorenzo Tallarigo, CEO of Genextra and Intercept director, is assuming the role of Chairman. Dr. Tallarigo stated, "This financing adds substantially to Genextra's investment in Intercept. With two positive Phase II studies last year, the company has made great progress in validating the therapeutic utility of INT-747 and the novel class of compounds it belongs to more broadly."

About Genextra S.p.A.

Genextra is a privately held holding of companies created in 2004 by a group of prominent Italian entrepreneurs and financial institutions in partnership with leading scientists from the European Institute of Oncology (IEO).

Genextra is dedicated to identifying innovative research in life science and to developing novel therapies and tools by creating successful business initiatives in a sustained and long term way.

Genextra, to date, controls four subsidiary companies: Intercept Pharmaceuticals, focused on chronic fibrotic and metabolic diseases, Congenia, targets pathways involved in mitochondrial oxidative stress, DAC, develops novel anticancer agents, and Tethis, develops thin-layered nanofilms for diagnostic applications.

About Intercept Pharmaceuticals

Intercept is a clinical stage biopharmaceutical company focused on discovering and developing small molecule drugs for the treatment of chronic fibrotic and metabolic diseases. The company's most advanced programs are focused on the development of modified bile acids that are selective for FXR, a nuclear receptor, and TGR5, a G protein-coupled receptor. Bile acid signaling through these receptors regulates key aspects of lipid, glucose and overall energy metabolism, while also serving to maintain the functional integrity of the liver, intestine and kidney, organs that are exposed to bile acid flux.

For more information about Genextra, please go to www.genextra.it

For more information about Intercept, please go to www.interceptpharma.com